PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Disease ReportsProstatic hyperplasia
MeSH D011470 - prostatic hyperplasia
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D011469:Prostatic diseases
0 Companies
0 Drugs
Success rate
D011470: 
Prostatic hyperplasia
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
TevaDoxazosin Doxazosin  2001-01-12   
Finasteride Finasteride  2006-06-19   
Prazosin Prazosin  1988-09-12   
Tamsulosin Tamsulosin  2010-04-27   
Terazosin Terazosin  2000-05-18   
MylanAlfuzosin Alfuzosin  2011-07-18   
Dutasteride Dutasteride  2016-06-14   
Finasteride Finasteride  2006-12-18   
Prazosin Prazosin  1989-05-16   
Tamsulosin Tamsulosin  2010-04-27   
Terazosin Terazosin  2000-02-11   
NATCO PharmaFinasteride Finasteride  2013-11-05   
CiplaAlfuzosin Alfuzosin  2012-01-17   
Finasteride Finasteride  2014-11-20   
Lupin ResearchSilodosin Silodosin  2018-12-03   
SandozTamsulosin Tamsulosin  2010-04-27   
Terazosin Terazosin  1998-12-31   
Chartwell PharmaceuticalsSilodosin Silodosin  2017-03-31   
Doxazosin Doxazosin  2000-10-18   
Dutasteride Dutasteride  2015-11-20   
Alfuzosin Alfuzosin  2011-07-18   
Terazosin Terazosin  2000-04-28   
Tamsulosin Tamsulosin  2019-10-17   
OrganonFinasteride Propecia  1997-12-19 $113 M Q4/23-Q3/24 
Finasteride Proscar  1992-06-19 $92 M Q4/23-Q3/24 
AbbVieSilodosin Rapaflo  2008-10-08   
1
2
3
4
5
6
7
>
Clinical Trials
Historical Success Rate
Phase 1
64%
9/14
Phase 2
70%
16/23
Phase 3
59%
16/27
Approved: 9Overall Success rate: 27%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Teva
1
2
3
4
5
>
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use